Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival

American Journal of Hematology

Volumn 90, Issue 9, 2015, Pages E197-E199

  Jaspers, Aurélie ^a   Baron, Frédéric ^a   Servais, Sophie ^a   Lejeune, Marie ^a   Willems, Évelyne ^a   Seidel, Laurence ^a   Hafraoui, Kaoutar ^a   Bonnet, Christophe ^a   Beguin, Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ERYTHROPOIETIN; ANTINEOPLASTIC AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BENIGN TUMOR; BLOOD TRANSFUSION; BRAIN DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; ESOPHAGITIS; FOLLOW UP; GASTRITIS; GLOMERULONEPHRITIS; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INFECTION; ISCHEMIC CARDIOMYOPATHY; LETTER; LONG TERM SURVIVAL; LUNG DISEASE; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PANCREATITIS; PERICARDITIS; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; THROMBOSIS; VASCULITIS; ALLOTRANSPLANTATION; COMPLICATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; OPPORTUNISTIC INFECTIONS; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; OPPORTUNISTIC INFECTIONS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84939522971     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24100     Document Type: Letter

References (6)

1. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009;373:1532-1542.
2. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
3. Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-1050.
4. Jaspers A, Baron F, Willems E, et al. Erythropoietin therapy after allogeneic hematopoietic cell transplantation: A prospective randomized trial. Blood 2014;124:33-41.
5. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-315.
6. Jaspers A, Baron F, Maertens J, et al. Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation. Am J Hematol, 2015;90:E133-134.